BRAF and neoplasm: The second-generation of RAF inhibitors, specifically targeting the mutated BRAF protein – such as vemurafenib, dabrafenib, and LGX818, potently inhibit MEK phosphorylation and cell growth in BRAF-mutated melanomas, being highly effective in inducing rapid tumor regression among melanoma patients (56–58).